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The challenge of silent rheumatic heart disease
Over the past 10 years, the number of studies on 
the burden of rheumatic heart disease in developing 
countries has substantially increased.1 These studies 
range from echocardiographic screening surveys 
of the prevalence of rheumatic heart disease 
in school children,2 to studies of incidence and 
progression,3,4 to investigations of the pathogenesis 
of the disease.5 The systematic review and meta-
analysis of prevalence studies of rheumatic heart 
disease by Martina Rothenbühler and colleagues6 in 
The Lancet Global Health is a timely summary of a decade 
of renewed focus by the international community on a 
neglected disease of poverty.
Rothenbühler and colleagues6 sought to assess the 
eﬀ ect of diﬀ erent screening methods (ie, auscultation 
vs echocardiography) on estimated prevalence of 
rheumatic heart disease among children and adolescents 
in endemic regions of the world. Of the 37 populations 
included, 17 were from Asia, nine Africa, seven Oceania, 
three Latin America, and one Europe. The pooled 
prevalence of rheumatic heart disease detected by cardiac 
auscultation was 2·9 per 1000 people (95% CI 1·7–5·0) 
and by echocardiography it was 12·9 per 1000 people 
(8·9–18·6), with substantial heterogeneity between 
individual reports for both screening tests (I²=99·0% 
and I²=94·9%, respectively). The previously reported7 
association between social inequality expressed by 
the Gini coeﬃ  cient and prevalence of rheumatic heart 
disease was also conﬁ rmed by Rothenbühler and 
colleagues (p=0·0002).6 The prevalence of clinically silent 
rheumatic heart disease (21·1 per 1000 people, 95% CI 
14·1–31·4) was about seven to eight times higher than 
that of clinically manifest disease (2·7 per 1000 people, 
1·6–4·4). As has been reported by others,8,9 prevalence 
progressively increased with advancing age, from 
4·7 per 1000 people (95% CI 0·0–11·2) in 5-year-old 
children, to 21·0 per 1000 people (6·8–35·1) in 16-year-
old adolescents, and the estimated overall incidence was 
1·6 per 1000 people (95% CI 0·8–2·3) and was constant 
across age categories (range 2·5, 95% CI 1·3–3·7 in 5-year-
old children to 1·7, 0·0–5·1 in 15-year-old adolescents). 
Unlike others who have noted a female preponderance 
in rheumatic heart disease prevalence,3 no sex-related 
diﬀ erences in prevalence of rheumatic heart disease were 
found (p=0·829).
Findings from the last major systematic review of the 
global prevalence of echocardiographic rheumatic heart 
disease showed that the highest calculated regional 
prevalence was in sub-Saharan Africa (5·7 cases per 
1000 people), indigenous people in the Paciﬁ c islands, 
Australia, and New Zealand (3·5 cases per 1000 people), 
and south central Asia (2·2 cases per 1000 people).10 
By contrast, the additional studies included in the 
present review show that southeast Asia is the new 
hot spot for echocardiographic rheumatic heart disease 
(28·0 cases per 1000 people, 95% CI 16·6–49·9), 
followed by Oceania (14·0 per 1000 people, 7·7–25·5), 
and Africa (7·9 per 1000 people, 2·9–21·4). The dramatic 
revival of rheumatic heart disease in the former Soviet 
republics of central Asia since the fall of the Berlin 
Wall in 198911 is consistent with the location of the 
epicentre of rheumatic heart disease in Asia reported in 
the present systematic review.6 The changing pattern 
of rheumatic heart disease in diﬀ erent regions of the 
world emphasises the importance of improving social 
conditions and access to primary health care for the 
control of rheumatic heart disease.
The pooled prevalence of clinical rheumatic heart 
disease (ie, presence of pathological murmur) seemed 
to be comparable whether it was measured by 
auscultation only (2·9 per 1000 people, 95% CI 1·7–5·0) 
or by echocardiography and auscultation (2·7 per 
1000 people, 1·6–4·4), which is remarkable. Consensus is 
emerging that this group of people with asymptomatic 
but clinically evident rheumatic heart disease should 
be considered for secondary antibiotic prophylaxis 
with penicillin to prevent progression to symptomatic 
disease, although there is no randomised evidence to 
support this recommendation.12 However, the challenge 
is how to manage treatment in children and adolescents 
with clinically silent rheumatic heart disease, whose 
prevalence was substantially higher than the cases 
of clinically manifest rheumatic heart disease in this 
systematic review. There is limited information on the 
natural history and virtually no evidence upon which to 
base the management of children and adolescents with 
asymptomatic subclinical rheumatic heart disease that 
is detected on active surveillance.12 The time has come 
to launch large-scale prospective studies of the natural 
history of latent rheumatic heart disease and trials to 
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assess the eﬃ  cacy of penicillin prophylaxis to prevent 
progression of disease.
The most important message of this systematic 
review and meta-analysis6 is that rheumatic heart 
disease remains a major public health problem in 
developing countries. The disease causes the  highest 
number of disability-adjusted life-years of all listed 
cardio vascular diseases among 10–14-year-olds 
(516·6 per 100 000 people, 95% CI 425·3–647·0) and 
the second highest number among children aged 
5–9 years (362·0 per 100 000 people, 294·6–462·0).13 
WHO has set a target of reducing premature mortality 
from rheumatic heart disease and other non-
communicable disease by 25% by the year 2025.14 
This target can be achieved and exceeded through the 
establishment of national rheumatic heart disease 
programmes that implement a comprehensive strategy 
for primary and secondary prevention of the disease, 
such as the Stop Rheumatic Heart Disease A.S.A.P. 
Programme, which has been launched in Africa.1 
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